NCT03993912 2026-04-07
IFM2017_03
University Hospital, Lille
Phase 3 Active not recruiting
Clinical Trials
142 trialsNCT00430365 2026-04-06
IFM2005-02
University Hospital, Toulouse
Phase 3 Completed
NCT01191060 2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT02659293 2026-03-04
Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
University of Chicago
Phase 3 Active not recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT03480360 2026-02-19
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
Phase 3 Active not recruiting
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT04751877 2026-02-10
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital
Phase 3 Active not recruiting
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT06216158 2026-02-02
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT04459416 2025-10-20
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT03823534 2025-10-15
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
Phase 3 Recruiting
NCT05556720 2025-10-03
BOOST-IC
Monash University
Phase 3 Active not recruiting
NCT01241708 2025-09-17
(Mel/MelVel)
Hackensack Meridian Health
Phase 3 Completed
NCT02066454 2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3 Completed
NCT03891914 2025-07-23
MYELOCHOL
University Hospital, Bordeaux
Phase 3 Completed
NCT06580223 2025-07-18
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Not yet recruiting
NCT00734877 2025-06-29
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT04096066 2025-01-15
KRdvsRd
Fondazione EMN Italy Onlus
Phase 3 Active not recruiting
NCT06561854 2024-12-18
FREEDOM
Assistance Publique - HĂ´pitaux de Paris
Phase 3 Recruiting
NCT03836014 2024-12-06
CONFIRM
Assistance Publique - HĂ´pitaux de Paris
Phase 3 Active not recruiting
NCT06588413 2024-11-22
FONDO-LOW
Augusta University
Phase 3 Recruiting
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01091831 2024-11-06
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT03595800 2024-10-04
HaploMUD-RIC
Institut Paoli-Calmettes
Phase 3 Completed
NCT06187441 2024-08-19
HOVON174MM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT00551928 2024-07-22
MPRvsMEL200
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT02215980 2024-07-22
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT06314698 2024-03-18
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
RenJi Hospital
Phase 3 Not yet recruiting
NCT06116734 2023-11-03
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Unknown
NCT01951885 2023-09-11
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Phase 3 Completed
NCT01063179 2023-06-29
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT02516696 2023-06-05
BiRd vs Rd
Weill Medical College of Cornell University
Phase 3 Terminated
NCT03948035 2023-05-06
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Wuerzburg University Hospital
Phase 3 Active not recruiting
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05802992 2023-04-07
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
Phase 3 Unknown
NCT05776940 2023-03-20
Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis
Air Force Military Medical University, China
Phase 3 Unknown
NCT01090089 2023-02-23
DSM XIII
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 3 Completed
NCT02544308 2022-12-23
IDRIS
University College, London
Phase 3 Active not recruiting
NCT02197221 2022-05-23
IFM2014-02
University Hospital, Toulouse
Phase 3 Completed
NCT02575144 2022-02-01
GEM-CLARIDEX
PETHEMA Foundation
Phase 3 Unknown
NCT04287660 2021-10-25
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT02495922 2021-09-10
GMMG-HD6
University of Heidelberg Medical Center
Phase 3 Completed
NCT05006469 2021-08-16
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Shengjing Hospital
Phase 3 Unknown